GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Cyclically Adjusted Price-to-FCF

Novonesis (Novozymes) B (OCSE:NSIS B) Cyclically Adjusted Price-to-FCF : 45.66 (As of Jul. 05, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Cyclically Adjusted Price-to-FCF?

As of today (2025-07-05), Novonesis (Novozymes) B's current share price is kr457.10. Novonesis (Novozymes) B's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was kr10.01. Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF for today is 45.66.

The historical rank and industry rank for Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

OCSE:NSIS B' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 29.16   Med: 44.6   Max: 59.76
Current: 45.67

During the past years, Novonesis (Novozymes) B's highest Cyclically Adjusted Price-to-FCF was 59.76. The lowest was 29.16. And the median was 44.60.

OCSE:NSIS B's Cyclically Adjusted Price-to-FCF is ranked worse than
67.73% of 564 companies
in the Chemicals industry
Industry Median: 23.605 vs OCSE:NSIS B: 45.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted free cash flow per share data for the three months ended in Mar. 2025 was kr0.816. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is kr10.01 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novonesis (Novozymes) B Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Cyclically Adjusted Price-to-FCF Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.35 60.61 37.19 37.08 41.68

Novonesis (Novozymes) B Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.08 41.81 44.22 41.68 40.06

Competitive Comparison of Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novonesis (Novozymes) B Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=457.10/10.01
=45.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novonesis (Novozymes) B's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.816/120.2000*120.2000
=0.816

Current CPI (Mar. 2025) = 120.2000.

Novonesis (Novozymes) B Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 1.956 100.200 2.346
201506 3.225 100.300 3.865
201509 1.315 100.200 1.577
201512 0.947 99.800 1.141
201603 2.050 100.200 2.459
201606 2.337 100.600 2.792
201609 2.860 100.200 3.431
201612 1.421 100.300 1.703
201703 2.421 101.200 2.876
201706 1.948 101.200 2.314
201709 2.673 101.800 3.156
201712 0.926 101.300 1.099
201803 1.358 101.700 1.605
201806 1.659 102.300 1.949
201809 3.724 102.400 4.371
201812 1.070 102.100 1.260
201903 1.449 102.900 1.693
201906 2.771 102.900 3.237
201909 2.910 102.900 3.399
201912 0.527 102.900 0.616
202003 2.914 103.300 3.391
202006 4.337 103.200 5.051
202009 2.354 103.500 2.734
202012 2.505 103.400 2.912
202103 2.503 104.300 2.885
202106 4.065 105.000 4.653
202109 3.153 105.800 3.582
202112 0.340 106.600 0.383
202203 1.377 109.900 1.506
202206 2.087 113.600 2.208
202209 1.668 116.400 1.722
202212 -1.145 115.900 -1.187
202303 -0.410 117.300 -0.420
202306 2.090 116.400 2.158
202309 3.992 117.400 4.087
202312 5.856 116.700 6.032
202403 2.155 118.400 2.188
202406 3.826 118.500 3.881
202412 4.570 118.900 4.620
202503 0.816 120.200 0.816

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novonesis (Novozymes) B  (OCSE:NSIS B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novonesis (Novozymes) B Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines